Rights to antibody drug by China’s Keymed change hands in Gilead acquisition of Ouro
AI Summary
Gilead Sciences will acquire Ouro Medicines for up to $2.18 billion to gain rights to CM336 (OM336), an antibody-based autoimmune disease treatment. Ouro licensed the rights to develop, manufacture, and commercialize CM336 outside of mainland China, Hong Kong, Macau, and Taiwan from China's Keymed Biosciences in 2024. Gilead aims to accelerate the global development of CM336, which they believe could be a best-in-class treatment. Keymed expects to receive approximately $250 million upfront and up to $70 million in milestone payments from the acquisition. The deal reflects Gilead's strategy to bolster its drug pipeline through acquisitions amid upcoming patent expirations.
Article Analysis
Key Claims (4)
AI-ExtractedThe transaction aimed to speed up the global development of CM336, an experimental treatment for autoimmune diseases.
Keymed expects to receive about US$250 million in upfront cash from Gilead, plus up to US$70 million in additional milestone payments.
Ouro holds exclusive rights to develop CM336 outside mainland China, Hong Kong, Macau and Taiwan, licensed from Keymed in 2024.
Gilead Sciences agreed to buy Ouro Medicines for up to US$2.18 billion.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis.
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.